Recently, there has been an increasing focus on the pursuit of targets considered to be less
druggable that offer potential for development of promising new therapeutic agents for the …

The prognosis of adult acute myeloid leukemia (AML) remains poor, with the long-term
survival rate less than 50%. However, the current paradigms of treatment are changing …

PURPOSE The FMS-related tyrosine kinase 3 (FLT3) inhibitor gilteritinib is standard therapy
for relapsed/refractory FLT3-mutated (FLT3 mut) acute myeloid leukemia (AML) but seldom …

Background Elderly patients (aged≥ 65 years) with acute myeloid leukaemia have poor
outcomes and no effective standard-of-care therapy exists. Treatment with hypomethylating …

Purpose Venetoclax is an orally bioavailable B-cell lymphoma 2 inhibitor. US Food and
Drug Administration and European Medicines Agency approval for patients with 17p deleted …

The antiapoptotic proteins BCL-2 and myeloid cell leukemia sequence 1 (MCL-1) promote
multiple myeloma (MM) cell survival. Venetoclax is a selective, orally bioavailable small …

Patients with relapsed/refractory (R/R) higher‐risk myelodysplastic syndromes (MDS) have a
dismal median overall survival (OS) after failing hypomethylating agent (HMA) treatment …

Purpose The effect of posaconazole, a strong cytochrome P450 3A (CYP3A) inhibitor and
commonly used antifungal agent, on the pharmacokinetic properties of venetoclax, a CYP3A …

Amorphous solid dispersions (ASDs) have gained attention as a formulation strategy in
recent years, with the potential to improve the apparent solubility and, hence, the oral …

Purpose: Small-cell lung cancer (SCLC) is an often-fatal neuroendocrine carcinoma usually
presenting as extensive disease, carrying a 3% 5-year survival. Despite notable advances in …